Polypeptide Labs

PolyPeptide Group is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of peptides and oligonucleotides for the pharmaceutical and biotech industries. The company provides a full range of services from early-stage custom synthesis to large-scale commercial manufacturing under Good Manufacturing Practice (GMP) conditions. With a heritage dating back to the 1950s through its roots in Ferring Pharmaceuticals, it has established a significant global footprint with facilities in Europe, the United States, and India. PolyPeptide supports a diverse portfolio of over 400 active projects, contributing to the development of treatments for metabolic diseases, oncology, and rare disorders. The company is publicly listed on the SIX Swiss Exchange and is recognized for its technical expertise in complex peptide chemistry and purification. Its business model focuses on long-term partnerships, supporting clients through the entire drug development lifecycle.